Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer.

Dagogo-Jack I, Azzolli CG, Fintelmann F, Mino-Kenudson M, Farago AF, Gainor JF, Jiang G, Piotrowska Z, Heist RS, Lennes IT, Temel JS, Mooradian MJ, Lin JJ, Digumarthy SR, Batten JM, Robinson H, Nose V, Rivera M, Nardi V, Dias-Santagata D, Le LP, Sequist LV, Pitman M, Shepard JO, Shaw AT, Iafrate AJ, Lennerz JK.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00299. Epub 2018 Jul 24.

2.

Artificial Intelligence Approach for Variant Reporting.

Zomnir MG, Lipkin L, Pacula M, Meneses ED, MacLeay A, Duraisamy S, Nadhamuni N, Al Turki SH, Zheng Z, Rivera M, Nardi V, Dias-Santagata D, Iafrate AJ, Le LP, Lennerz JK.

JCO Clin Cancer Inform. 2018;2018. doi: 10.1200/CCI.16.00079. Epub 2018 Mar 22.

3.

Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.

Piotrowska Z, Isozaki H, Lennerz JK, Gainor JF, Lennes IT, Zhu VW, Marcoux N, Banwait MK, Digumarthy SR, Su W, Yoda S, Riley AK, Nangia V, Lin JJ, Nagy RJ, Lanman RB, Dias-Santagata D, Mino-Kenudson M, Iafrate AJ, Heist RS, Shaw AT, Evans EK, Clifford C, Ou SI, Wolf B, Hata AN, Sequist LV.

Cancer Discov. 2018 Dec;8(12):1529-1539. doi: 10.1158/2159-8290.CD-18-1022. Epub 2018 Sep 26.

PMID:
30257958
4.

Novel gene fusions in secretory carcinoma of the salivary glands: enlarging the ETV6 family.

Guilmette J, Dias-Santagata D, Nosé V, Lennerz JK, Sadow PM.

Hum Pathol. 2018 Aug 18. pii: S0046-8177(18)30316-2. doi: 10.1016/j.humpath.2018.08.011. [Epub ahead of print]

PMID:
30130630
5.

Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer.

Piotrowska Z, Hazar-Rethinam M, Rizzo C, Nadres B, Van Seventer EE, Shahzade HA, Lennes IT, Iafrate AJ, Dias-Santagata D, Leshchiner I, Jessop NA, Hu H, Digumarthy SR, Nagy RJ, Lanman RB, Moody S, Niederst MJ, Engelman JA, Hata AN, Corcoran RB, Sequist LV.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00263. Epub 2018 Jul 16.

6.

Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma.

Gopal RK, Kübler K, Calvo SE, Polak P, Livitz D, Rosebrock D, Sadow PM, Campbell B, Donovan SE, Amin S, Gigliotti BJ, Grabarek Z, Hess JM, Stewart C, Braunstein LZ, Arndt PF, Mordecai S, Shih AR, Chaves F, Zhan T, Lubitz CC, Kim J, Iafrate AJ, Wirth L, Parangi S, Leshchiner I, Daniels GH, Mootha VK, Dias-Santagata D, Getz G, McFadden DG.

Cancer Cell. 2018 Aug 13;34(2):242-255.e5. doi: 10.1016/j.ccell.2018.06.013.

PMID:
30107175
7.

Complete Remission Following Pembrolizumab in a Woman with Mismatch Repair-Deficient Endometrial Cancer and a Germline BRCA1 Mutation.

Dizon DS, Dias-Santagata D, Bregar A, Sullivan L, Filipi J, DiTavi E, Miller L, Ellisen L, Birrer M, DelCarmen M.

Oncologist. 2018 Jun;23(6):650-653. doi: 10.1634/theoncologist.2017-0526. Epub 2018 Feb 22.

PMID:
29472312
8.

Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAFV600E Colorectal Cancer.

Hazar-Rethinam M, Kleyman M, Han GC, Liu D, Ahronian LG, Shahzade HA, Chen L, Parikh AR, Allen JN, Clark JW, Kwak EL, Faris JE, Murphy JE, Hong TS, Van Seventer EE, Nadres B, Hong CB, Gurski JM Jr, Jessop NA, Dias-Santagata D, Iafrate AJ, Van Allen EM, Corcoran RB.

Cancer Discov. 2018 Apr;8(4):417-427. doi: 10.1158/2159-8290.CD-17-1227. Epub 2018 Feb 5.

PMID:
29431697
9.

Primary Benign and Malignant Thyroid Neoplasms With Signet Ring Cells: Cytologic, Histologic, and Molecular Features.

Farhat NA, Onenerk AM, Krane JF, Dias-Santagata D, Sadow PM, Faquin WC.

Am J Clin Pathol. 2017 Sep 1;148(3):251-258. doi: 10.1093/ajcp/aqx074.

PMID:
28821194
10.

Invasive follicular variant of papillary thyroid cancer harboring the NRAS mutation Q61K and presenting with bone metastasis-A case report.

Mehrzad R, Nishino M, Nucera C, Dias-Santagata D, Hennessey JV, Hasselgren PO.

Int J Surg Case Rep. 2017;38:180-184. doi: 10.1016/j.ijscr.2017.06.067. Epub 2017 Jul 20.

11.

KIT mutations and CD117 overexpression are markers of better progression-free survival in vulvar melanomas.

Dias-Santagata D, Selim MA, Su Y, Peng Y, Vollmer R, Chłopik A, Tell-Marti G, Paral KM, Shalin SC, Shea CR, Puig S, Fernandez-Figueras MT, Biernat W, Ryś J, Marszalek A, Hoang MP.

Br J Dermatol. 2017 Nov;177(5):1376-1384. doi: 10.1111/bjd.15836. Epub 2017 Nov 5. Erratum in: Br J Dermatol. 2018 Mar;178(3):815.

PMID:
28734009
12.

Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor.

Alvarez-Breckenridge C, Miller JJ, Nayyar N, Gill CM, Kaneb A, D'Andrea M, Le LP, Lee J, Cheng J, Zheng Z, Butler WE, Multani P, Chow Maneval E, Ha Paek S, Toyota BD, Dias-Santagata D, Santagata S, Romero J, Shaw AT, Farago AF, Yip S, Cahill DP, Batchelor TT, Iafrate AJ, Brastianos PK.

NPJ Precis Oncol. 2017 Mar 20;1(1):5. doi: 10.1038/s41698-017-0009-y. eCollection 2017.

13.

Clear Cell Change in Thyroid Carcinoma: A Clinicopathologic and Molecular Study with Identification of Variable Genetic Anomalies.

Cipriani NA, Agarwal S, Dias-Santagata D, Faquin WC, Sadow PM.

Thyroid. 2017 Jun;27(6):819-824. doi: 10.1089/thy.2016.0631. Epub 2017 Apr 12.

PMID:
28293986
14.
15.

Immunohistochemical Detection of ROS1 Fusion.

Su Y, Goncalves T, Dias-Santagata D, Hoang MP.

Am J Clin Pathol. 2017 Jan 1;147(1):77-82. doi: 10.1093/ajcp/aqw201.

PMID:
28007702
16.

De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers.

Lucena-Araujo AR, Moran JP, VanderLaan PA, Dias-Santagata D, Folch E, Majid A, Kent MS, Gangadharan SP, Rangachari D, Huberman MS, Kobayashi SS, Costa DB.

Lung Cancer. 2016 Sep;99:17-22. doi: 10.1016/j.lungcan.2016.06.006. Epub 2016 Jun 14.

17.

Ki-67, p53, and p16 expression, and G691S RET polymorphism in desmoplastic melanoma (DM): A clinicopathologic analysis of predictors of outcome.

Lawrence NF, Hammond MR, Frederick DT, Su Y, Dias-Santagata D, Deng A, Selim MA, Mahalingam M, Flaherty KT, Hoang MP.

J Am Acad Dermatol. 2016 Sep;75(3):595-602. doi: 10.1016/j.jaad.2016.04.059.

PMID:
27543214
18.

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.

Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, Dagogo-Jack I, Gadgeel S, Schultz K, Singh M, Chin E, Parks M, Lee D, DiCecca RH, Lockerman E, Huynh T, Logan J, Ritterhouse LL, Le LP, Muniappan A, Digumarthy S, Channick C, Keyes C, Getz G, Dias-Santagata D, Heist RS, Lennerz J, Sequist LV, Benes CH, Iafrate AJ, Mino-Kenudson M, Engelman JA, Shaw AT.

Cancer Discov. 2016 Oct;6(10):1118-1133. Epub 2016 Jul 18.

19.

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.

Heist RS, Sequist LV, Borger D, Gainor JF, Arellano RS, Le LP, Dias-Santagata D, Clark JW, Engelman JA, Shaw AT, Iafrate AJ.

J Thorac Oncol. 2016 Aug;11(8):1242-1245. doi: 10.1016/j.jtho.2016.06.013. Epub 2016 Jun 22.

20.

Colorectal cancer in Crohn's colitis is comparable to sporadic colorectal cancer.

Lennerz JK, van der Sloot KWJ, Le LP, Batten JM, Han JY, Fan KC, Siegel CA, Srivastava A, Park DY, Chen JH, Sands BE, Korzenik JR, Odze RD, Dias-Santagata D, Borger DR, Khalili H, Iafrate AJ, Lauwers GY.

Int J Colorectal Dis. 2016 May;31(5):973-982. doi: 10.1007/s00384-016-2574-x. Epub 2016 Mar 30.

PMID:
27026089
21.

Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.

Abedalthagafi M, Bi WL, Aizer AA, Merrill PH, Brewster R, Agarwalla PK, Listewnik ML, Dias-Santagata D, Thorner AR, Van Hummelen P, Brastianos PK, Reardon DA, Wen PY, Al-Mefty O, Ramkissoon SH, Folkerth RD, Ligon KL, Ligon AH, Alexander BM, Dunn IF, Beroukhim R, Santagata S.

Neuro Oncol. 2016 May;18(5):649-55. doi: 10.1093/neuonc/nov316. Epub 2016 Jan 28.

22.

Immunohistochemical Detection of NRASQ61R Mutation in Diverse Tumor Types.

Dias-Santagata D, Su Y, Hoang MP.

Am J Clin Pathol. 2016 Jan;145(1):29-34. doi: 10.1093/ajcp/aqv015.

PMID:
26712868
23.

Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.

Duquette M, Sadow PM, Husain A, Sims JN, Antonello ZA, Fischer AH, Song C, Castellanos-Rizaldos E, Makrigiorgos GM, Kurebayashi J, Nose V, Van Hummelen P, Bronson RT, Vinco M, Giordano TJ, Dias-Santagata D, Pandolfi PP, Nucera C.

Oncotarget. 2015 Dec 15;6(40):42445-67. doi: 10.18632/oncotarget.6442.

24.

Next-Generation Sequencing and Fluorescence in Situ Hybridization Have Comparable Performance Characteristics in the Analysis of Pancreaticobiliary Brushings for Malignancy.

Dudley JC, Zheng Z, McDonald T, Le LP, Dias-Santagata D, Borger D, Batten J, Vernovsky K, Sweeney B, Arpin RN, Brugge WR, Forcione DG, Pitman MB, Iafrate AJ.

J Mol Diagn. 2016 Jan;18(1):124-30. doi: 10.1016/j.jmoldx.2015.08.002. Epub 2015 Nov 18.

PMID:
26596524
25.

Identification of insertions in PTEN and TP53 in anaplastic thyroid carcinoma with angiogenic brain metastasis.

Sadow PM, Dias-Santagata D, Zheng Z, Lin DT, Le LP, Nucera C.

Endocr Relat Cancer. 2015 Dec;22(6):L23-8. doi: 10.1530/ERC-15-0198. No abstract available.

26.

Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Platt MY, Fathi AT, Borger DR, Brunner AM, Hasserjian RP, Balaj L, Lum A, Yip S, Dias-Santagata D, Zheng Z, Le LP, Graubert TA, Iafrate AJ, Nardi V.

J Mol Diagn. 2015 Nov;17(6):661-8. doi: 10.1016/j.jmoldx.2015.06.004. Epub 2015 Aug 30.

27.

Genomic and immunohistochemical analysis in human adrenal cortical neoplasia reveal beta-catenin mutations as potential prognostic biomarker.

Kovach AE, Nucera C, Lam QT, Nguyen A, Dias-Santagata D, Sadow PM.

Discoveries (Craiova). 2015 Apr-Jun;3(2). pii: e40.

28.

Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts.

Jones M, Zheng Z, Wang J, Dudley J, Albanese E, Kadayifci A, Dias-Santagata D, Le L, Brugge WR, Fernandez-del Castillo C, Mino-Kenudson M, Iafrate AJ, Pitman MB.

Gastrointest Endosc. 2016 Jan;83(1):140-8. doi: 10.1016/j.gie.2015.06.047. Epub 2015 Aug 5.

PMID:
26253016
29.

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.

Piotrowska Z, Niederst MJ, Karlovich CA, Wakelee HA, Neal JW, Mino-Kenudson M, Fulton L, Hata AN, Lockerman EL, Kalsy A, Digumarthy S, Muzikansky A, Raponi M, Garcia AR, Mulvey HE, Parks MK, DiCecca RH, Dias-Santagata D, Iafrate AJ, Shaw AT, Allen AR, Engelman JA, Sequist LV.

Cancer Discov. 2015 Jul;5(7):713-22. doi: 10.1158/2159-8290.CD-15-0399. Epub 2015 May 1.

30.

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.

Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DJ; LCMC Investigators.

J Thorac Oncol. 2015 May;10(5):768-777. doi: 10.1097/JTO.0000000000000516.

31.

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.

Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, Godfrey JT, Nishimura K, Lynch KD, Mermel CH, Lockerman EL, Kalsy A, Gurski JM Jr, Bahl S, Anderka K, Green LM, Lennon NJ, Huynh TG, Mino-Kenudson M, Getz G, Dias-Santagata D, Iafrate AJ, Engelman JA, Garraway LA, Corcoran RB.

Cancer Discov. 2015 Apr;5(4):358-67. doi: 10.1158/2159-8290.CD-14-1518. Epub 2015 Feb 11.

32.

Identification of oncogenic mutations and gene fusions in the follicular variant of papillary thyroid carcinoma.

McFadden DG, Dias-Santagata D, Sadow PM, Lynch KD, Lubitz C, Donovan SE, Zheng Z, Le L, Iafrate AJ, Daniels GH.

J Clin Endocrinol Metab. 2014 Nov;99(11):E2457-62. doi: 10.1210/jc.2014-2611. Epub 2014 Aug 22.

33.

The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.

Izar B, Zhou H, Heist RS, Azzoli CG, Muzikansky A, Scribner EE, Bernardo LA, Dias-Santagata D, Iafrate AJ, Lanuti M.

J Thorac Oncol. 2014 Sep;9(9):1363-9. doi: 10.1097/JTO.0000000000000266.

34.

The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy.

Scherz-Shouval R, Santagata S, Mendillo ML, Sholl LM, Ben-Aharon I, Beck AH, Dias-Santagata D, Koeva M, Stemmer SM, Whitesell L, Lindquist S.

Cell. 2014 Jul 31;158(3):564-78. doi: 10.1016/j.cell.2014.05.045.

35.

Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery.

Santagata S, Eberlin LS, Norton I, Calligaris D, Feldman DR, Ide JL, Liu X, Wiley JS, Vestal ML, Ramkissoon SH, Orringer DA, Gill KK, Dunn IF, Dias-Santagata D, Ligon KL, Jolesz FA, Golby AJ, Cooks RG, Agar NY.

Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11121-6. doi: 10.1073/pnas.1404724111. Epub 2014 Jun 30.

36.

Pulmonary adenocarcinoma mutation profile in smokers with smoking-related interstitial fibrosis.

Primiani A, Dias-Santagata D, Iafrate AJ, Kradin RL.

Int J Chron Obstruct Pulmon Dis. 2014 May 24;9:525-31. doi: 10.2147/COPD.S61932. eCollection 2014.

37.

VE1 antibody immunoreactivity in normal anterior pituitary and adrenal cortex without detectable BRAF V600E mutations.

Mordes DA, Lynch K, Campbell S, Dias-Santagata D, Nose V, Louis DN, Hoang MP.

Am J Clin Pathol. 2014 Jun;141(6):811-5. doi: 10.1309/AJCP37TLZLTUAOJL.

PMID:
24838325
38.

Standardized decision support in next generation sequencing reports of somatic cancer variants.

Dienstmann R, Dong F, Borger D, Dias-Santagata D, Ellisen LW, Le LP, Iafrate AJ.

Mol Oncol. 2014 Jul;8(5):859-73. doi: 10.1016/j.molonc.2014.03.021. Epub 2014 Apr 4. Review.

39.

Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.

Wakimoto H, Tanaka S, Curry WT, Loebel F, Zhao D, Tateishi K, Chen J, Klofas LK, Lelic N, Kim JC, Dias-Santagata D, Ellisen LW, Borger DR, Fendt SM, Vander Heiden MG, Batchelor TT, Iafrate AJ, Cahill DP, Chi AS.

Clin Cancer Res. 2014 Jun 1;20(11):2898-909. doi: 10.1158/1078-0432.CCR-13-3052. Epub 2014 Apr 8.

40.

Mutational analysis and clinical correlation of metastatic colorectal cancer.

Russo AL, Borger DR, Szymonifka J, Ryan DP, Wo JY, Blaszkowsky LS, Kwak EL, Allen JN, Wadlow RC, Zhu AX, Murphy JE, Faris JE, Dias-Santagata D, Haigis KM, Ellisen LW, Iafrate AJ, Hong TS.

Cancer. 2014 May 15;120(10):1482-90. doi: 10.1002/cncr.28599. Epub 2014 Feb 5.

41.

Hobnail variant of papillary thyroid carcinoma: an institutional case series and molecular profile.

Lubitz CC, Economopoulos KP, Pawlak AC, Lynch K, Dias-Santagata D, Faquin WC, Sadow PM.

Thyroid. 2014 Jun;24(6):958-65. doi: 10.1089/thy.2013.0573. Epub 2014 Mar 6.

42.

Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.

Brastianos PK, Taylor-Weiner A, Manley PE, Jones RT, Dias-Santagata D, Thorner AR, Lawrence MS, Rodriguez FJ, Bernardo LA, Schubert L, Sunkavalli A, Shillingford N, Calicchio ML, Lidov HG, Taha H, Martinez-Lage M, Santi M, Storm PB, Lee JY, Palmer JN, Adappa ND, Scott RM, Dunn IF, Laws ER Jr, Stewart C, Ligon KL, Hoang MP, Van Hummelen P, Hahn WC, Louis DN, Resnick AC, Kieran MW, Getz G, Santagata S.

Nat Genet. 2014 Feb;46(2):161-5. doi: 10.1038/ng.2868. Epub 2014 Jan 12.

43.

Inactivation of the tumor suppressor WTX in a subset of pediatric tumors.

Akhavanfard S, Vargas SO, Han M, Nitta M, Chang CB, Le LP, Fazlollahi L, Nguyen Q, Ma Y, Cosper A, Dias-Santagata D, Han JY, Bergethon K, Borger DR, Ellisen LW, Pomeroy SL, Haber DA, Iafrate AJ, Rivera MN.

Genes Chromosomes Cancer. 2014 Jan;53(1):67-77. doi: 10.1002/gcc.22118. Epub 2013 Nov 5.

PMID:
24249259
44.

Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas.

Routhier CA, Mochel MC, Lynch K, Dias-Santagata D, Louis DN, Hoang MP.

Hum Pathol. 2013 Nov;44(11):2563-70. doi: 10.1016/j.humpath.2013.06.018. Epub 2013 Sep 24.

PMID:
24071017
45.

The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.

Izar B, Sequist L, Lee M, Muzikansky A, Heist R, Iafrate J, Dias-Santagata D, Mathisen D, Lanuti M.

Ann Thorac Surg. 2013 Sep;96(3):962-8. doi: 10.1016/j.athoracsur.2013.05.091. Epub 2013 Aug 8.

PMID:
23932319
46.

ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.

Gainor JF, Varghese AM, Ou SH, Kabraji S, Awad MM, Katayama R, Pawlak A, Mino-Kenudson M, Yeap BY, Riely GJ, Iafrate AJ, Arcila ME, Ladanyi M, Engelman JA, Dias-Santagata D, Shaw AT.

Clin Cancer Res. 2013 Aug 1;19(15):4273-81. doi: 10.1158/1078-0432.CCR-13-0318. Epub 2013 May 31.

47.

BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults.

Chi AS, Batchelor TT, Yang D, Dias-Santagata D, Borger DR, Ellisen LW, Iafrate AJ, Louis DN.

J Clin Oncol. 2013 May 10;31(14):e233-6. doi: 10.1200/JCO.2012.46.0220. Epub 2013 Apr 1. No abstract available.

PMID:
23547069
48.

Characteristics of lung cancers harboring NRAS mutations.

Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, Franklin WA, Riely GJ, Sos ML, Kris MG, Dias-Santagata D, Ladanyi M, Bunn PA Jr, Pao W.

Clin Cancer Res. 2013 May 1;19(9):2584-91. doi: 10.1158/1078-0432.CCR-12-3173. Epub 2013 Mar 20.

49.

Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models.

Corcoran RB, Cheng KA, Hata AN, Faber AC, Ebi H, Coffee EM, Greninger P, Brown RD, Godfrey JT, Cohoon TJ, Song Y, Lifshits E, Hung KE, Shioda T, Dias-Santagata D, Singh A, Settleman J, Benes CH, Mino-Kenudson M, Wong KK, Engelman JA.

Cancer Cell. 2013 Jan 14;23(1):121-8. doi: 10.1016/j.ccr.2012.11.007. Epub 2012 Dec 13.

50.

Basal cell carcinoma with osteosarcomatous component.

Tse JY, Pawlak AC, Boussahmain C, Routhier CA, Dias-Santagata D, Kalomiris D, Hoang MP.

Am J Dermatopathol. 2013 Apr;35(2):261-5. doi: 10.1097/DAD.0b013e31826b352b.

PMID:
23221485

Supplemental Content

Loading ...
Support Center